Keywords: fda, accepts, nda, watson, oab, gel, usa

FDA accepts NDA on Watson's OAB gel

Article | 09 June 2008

Print This

The USA's Watson Pharmaceuticals says that its New Drug Application for oxybutynin chloride topical gel has been accepted for filing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in